Literature DB >> 29016779

Is less more? Impact of different ablation protocols on periprocedural complications in second-generation cryoballoon based pulmonary vein isolation.

Laura Rottner1, Thomas Fink1, Christian-Hendrik Heeger1, Michael Schlüter2, Britta Goldmann3, Christine Lemes1, Tilman Maurer1, Bruno Reißmann1, Enida Rexha1, Johannes Riedl1, Francesco Santoro1, Peter Wohlmuth2, Shibu Mathew1, Christian Sohns1, Feifan Ouyang1, Karl-Heinz Kuck1, Andreas Metzner1.   

Abstract

Aims: Second-generation cryoballoon (CB2) based pulmonary vein isolation (PVI) has emerged as an effective treatment option for symptomatic atrial fibrillation (AF). The current study sought to assess the impact of different ablation protocols on the incidence and characteristics of procedural complications in a large patient cohort. Methods and results: A total of 563 consecutive patients with symptomatic AF who underwent CB2-based ablation between July 2012 and January 2016, were assessed. Three different ablation protocols were applied and characterized by (#1) a bonus-freeze following PVI, (#2) no bonus-freeze after PVI, and (#3) a 'time-to-effect'-guided strategy. Major complications occurred in 30/563 patients (5.3%) with phrenic nerve palsy (PNP) as the most frequent complication occurring in 2.7% of the cases. The overall incidence of complications was significantly lower in patients treated with a 'time-to-effect' guided ablation strategy compared with the other ablation protocols (8.1% [17/211] (protocol #1+#2) vs. 3.7% [13/352] (protocol #3), respectively; P = 0.026). The 'time-to-effect' guided ablation protocol was associated with less applied freeze-cycles and shorter freeze-cycle durations. Additionally, shorter procedure times, radiation exposures and lower volumes of contrast medium needed were assessed for the 'time-to-effect' guided protocol as compared with the other ablation protocols.
Conclusion: The overall incidence of complications was 5.3% in our analysis. The most frequent complication was PNP. The use of a time-to-effect guided ablation protocol was associated with a lower incidence of major complications compared with a bonus-freeze and no bonus-freeze protocol.

Entities:  

Mesh:

Year:  2018        PMID: 29016779     DOI: 10.1093/europace/eux219

Source DB:  PubMed          Journal:  Europace        ISSN: 1099-5129            Impact factor:   5.214


  12 in total

Review 1.  The Impact of Advances in Atrial Fibrillation Ablation Devices on the Incidence and Prevention of Complications.

Authors:  Fehmi Keçe; Katja Zeppenfeld; Serge A Trines
Journal:  Arrhythm Electrophysiol Rev       Date:  2018-08

2.  Time-to-effect guided pulmonary vein isolation utilizing the third-generation versus second generation cryoballoon: One year clinical success.

Authors:  Christian-Hendrik Heeger; Christopher Schuette; Valentina Seitelberger; Erik Wissner; Andreas Rillig; Shibu Mathew; Bruno Reissmann; Christine Lemes; Tilman Maurer; Thomas Fink; Osamu Inaba; Naotaka Hashiguchi; Francesco Santoro; Feifan Ouyang; Karl-Heinz Kuck; Andreas Metzner
Journal:  Cardiol J       Date:  2018-06-20       Impact factor: 2.737

Review 3.  Acute Procedural Complications of Cryoballoon Ablation: A Comprehensive Review.

Authors:  Tolga Aksu; Kivanc Yalin; Tumer Erdem Guler; Serdar Bozyel; Christian-H Heeger; Roland R Tilz
Journal:  J Atr Fibrillation       Date:  2019-10-31

Review 4.  [Catheter ablation : Developments and technique selection].

Authors:  L Yahsaly; J Siebermair; R Wakili
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2022-02-18

Review 5.  [Practical guide for safe and efficient cryoballoon ablation for atrial fibrillation : Practical procedure, tips and tricks].

Authors:  Julian Chun; Tilman Maurer; Andreas Rillig; Stefano Bordignon; Leon Iden; Sonia Busch; Daniel Steven; Roland R Tilz; Dong-In Shin; Heidi Estner; Felix Bourier; David Duncker; Philipp Sommer; Nils-Christian Ewertsen; Henning Jansen; Victoria Johnson; Livio Bertagnolli; Till Althoff; Andreas Metzner
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2021-11-04

6.  Individualized or fixed approach to pulmonary vein isolation utilizing the fourth-generation cryoballoon in patients with paroxysmal atrial fibrillation: the randomized INDI-FREEZE trial.

Authors:  Christian Hendrik Heeger; Sorin Stefan Popescu; Roza Saraei; Bettina Kirstein; Sascha Hatahet; Omar Samara; Anna Traub; Marcel Fehe; Gabriele D'Ambrosio; Ahmad Keelani; Michael Schlüter; Charlotte Eitel; Julia Vogler; Karl Heinz Kuck; Roland Richard Tilz
Journal:  Europace       Date:  2022-07-15       Impact factor: 5.486

7.  Optimizing ablation duration using dormant conduction to reveal incomplete isolation with the second generation cryoballoon: A randomized controlled trial.

Authors:  Fehmi Keçe; Marta de Riva; Yoshihisa Naruse; Reza Alizadeh Dehnavi; Adrianus P Wijnmaalen; Martin J Schalij; Katja Zeppenfeld; Serge A Trines
Journal:  J Cardiovasc Electrophysiol       Date:  2019-03-29

8.  Shorter cryoballoon applications times do effect efficacy but result in less phrenic nerve injury: Results of the randomized 123 study.

Authors:  Marleen M D Molenaar; Carl C Timmermans; Tim Hesselink; Marcoen F Scholten; Rachel M A Ter Bekke; Justin G L M Luermans; Marjolein Brusse-Keizer; Karin Kraaier; Bernard Ten Haken; Jan G Grandjean; Kevin Vernooy; Jurren M van Opstal
Journal:  Pacing Clin Electrophysiol       Date:  2019-03-05       Impact factor: 1.976

Review 9.  Catheter Ablation of Atrial Fibrillation: State of the Art and Future Perspectives.

Authors:  Laura Rottner; Barbara Bellmann; Tina Lin; Bruno Reissmann; Tobias Tönnis; Ruben Schleberger; Moritz Nies; Christiane Jungen; Leon Dinshaw; Niklas Klatt; Jannis Dickow; Paula Münkler; Christian Meyer; Andreas Metzner; Andreas Rillig
Journal:  Cardiol Ther       Date:  2020-01-02

10.  Feasibility, safety, and acute efficacy of the fourth-generation cryoballoon for ablation of atrial fibrillation: Another step forward?

Authors:  Laura Rottner; Shibu Mathew; Bruno Reissmann; Laura Warneke; Isabell Martin; Christine Lemes; Tilman Maurer; Peter Wohlmuth; Feifan Ouyang; Karl-Heinz Kuck; Andreas Metzner; Andreas Rillig
Journal:  Clin Cardiol       Date:  2020-02-25       Impact factor: 2.882

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.